antiplatelet

This page covers all antiplatelet drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting COX-1, P2Y12 receptor, P2Y12 receptor, COX-1.

Targets

COX-1 · P2Y12 receptor · P2Y12 receptor, COX-1

Marketed (1)

• Preventative Medication (PM) · NYU Langone Health · Cardiovascular
  Prevents cardiovascular events by inhibiting platelet aggregation.

Phase 3 pipeline (7)

• Standard antiplatelet · Beijing Tiantan Hospital · Cardiovascular
  Standard antiplatelet drugs work by inhibiting platelet activation and aggregation, preventing blood clots from forming.
• Short DAPT · Korea University Guro Hospital · Cardiovascular
  Short DAPT involves a reduced duration of dual antiplatelet therapy to minimize bleeding risks while maintaining cardiovascular protection.
• clopidogrel by chewing · Sheba Medical Center · Cardiovascular
  Clopidogrel inhibits platelet activation and aggregation by irreversibly inhibiting the P2Y12 receptor.
• Ticlopidine + Ginko biloba · Samsung Medical Center · Cardiovascular
  Ticlopidine inhibits platelet aggregation by irreversibly blocking ADP receptors on platelets, while Ginkgo biloba has antioxidant and anti-inflammatory properties.
• Ticagrelor plus ASA · University of Athens · Cardiovascular
  Ticagrelor plus ASA inhibits platelet activation and aggregation by blocking the P2Y12 receptor and irreversibly inhibiting COX-1.
• The Clopidogrel · Sichuan Provincial People's Hospital · Cardiovascular
  Clopidogrel inhibits platelet activation and aggregation by irreversibly inhibiting the P2Y12 receptor.
• clopidogrel plus aspirin · Catholic University of the Sacred Heart · Cardiovascular
  Clopidogrel is an antiplatelet medication that inhibits platelet activation and aggregation by irreversibly binding to the P2Y12 receptor, while aspirin is an antiplatelet medication that inhibits platelet aggregation by irreversibly acetylating the cyclooxygenase-1 enzyme.

Phase 2 pipeline (2)

• DAPT, Statin · Samsung Medical Center · Cardiovascular
  DAPT inhibits platelet aggregation by blocking the P2Y12 receptor.
• Discontinue Clopidogrel · Icahn School of Medicine at Mount Sinai · Cardiovascular
  Clopidogrel is a prodrug that is metabolized to its active form by CYP450 enzymes, primarily CYP2C19, which irreversibly inhibits platelet aggregation by blocking the P2Y12 receptor on platelets.

Phase 1 pipeline (1)

• Antiplatelet or Anticoagulant Therapy · Syntrillo, Inc · Cardiovascular
  Inhibits platelet aggregation